Jazz Pharmaceuticals’ (JAZZ) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report published on Thursday, Benzinga reports. The firm currently has a $200.00 price target on the specialty pharmaceutical company’s stock.

Several other brokerages also recently commented on JAZZ. Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an outperform rating on the stock in a report on Thursday. UBS Group decreased their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a neutral rating for the company in a research note on Tuesday, July 2nd. Cantor Fitzgerald reaffirmed an overweight rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Barclays lowered their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating on the stock in a research note on Friday, May 3rd. Finally, Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an equal weight rating on the stock in a research report on Friday, July 12th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus target price of $175.20.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $2.06 during midday trading on Thursday, hitting $111.20. 238,932 shares of the company traded hands, compared to its average volume of 683,345. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $146.70. The stock has a market capitalization of $7.01 billion, a price-to-earnings ratio of 19.65, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58. The company has a quick ratio of 1.90, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The business has a 50 day simple moving average of $107.82 and a 200-day simple moving average of $114.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in JAZZ. State of Michigan Retirement System increased its stake in shares of Jazz Pharmaceuticals by 1.2% in the fourth quarter. State of Michigan Retirement System now owns 17,364 shares of the specialty pharmaceutical company’s stock valued at $2,136,000 after buying an additional 200 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Jazz Pharmaceuticals by 347.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,280 shares of the specialty pharmaceutical company’s stock worth $895,000 after purchasing an additional 5,654 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $7,201,000. Prime Capital Investment Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 4.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after purchasing an additional 108 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in Jazz Pharmaceuticals by 94.2% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock worth $11,210,000 after purchasing an additional 44,414 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.